Physician profile
Amy Marshall
NPI 1992931679
$6,801.87
in general payments reported to CMS, 2019-2025
45 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $1,089 · 2021: $896 · 2022: $1,136 · 2023: $1,030 · 2024: $1,184 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,074.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,710.36 | 2019-2025 | |
| Amgen INC. | $601.50 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $525.12 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.73 | 2020-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $321.10 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $312.99 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $305.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.40 | 2020-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $254.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $159.55 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $144.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $137.48 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Allergan, INC. | $130.02 | 2020 | |
| Inspire Medical Systems, INC. | $112.34 | 2023-2025 | Inspire |
| Abbott Laboratories | $111.52 | 2021-2025 | Freestyle Libre 3 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.